Piramal Invests Almost $75m In Expanding Manufacturing Capacity
Company Expects Part Of Its UK Manufacturing Site To Be Functional By Next Year
Executive Summary
Piramal Pharma’s Piramal Pharma Solutions contract development and manufacturing organization has invested around $75m in expanding its antibody-drug conjugate capabilities at its Grangemouth facility in Scotland and investing in a new active pharmaceutical ingredient infrastructure at the Morpeth facility in England.
You may also be interested in...
India’s Piramal Pharma Rings The Bell On Domestic Stock Exchange Listings
Piramal Pharma is “embarking on a new journey as a focused pharma entity,” as it seeks to “identify and secure inorganic and organic growth opportunities to generate consistent shareholder value.”
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.